📰 Hemescreen Panel News
Hemescreen Panel News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Hemescreen Panel. Real-time updates on events, politics, business and more.
June 17, 2023
Precipio (NASDAQ:PRPO – Get Rating) had its price objective lowered by Alliance Global Partners from $2.85 to $2.00 in a research report sent to investors on Tuesday, The Fly reports. Precipio Stock Performance NASDAQ PRPO opened at $0.40 on Tuesday. The company has a 50 day moving average of $0.60 and a 200-day moving average […]
June 14, 2023
Precipio, Inc. (NASDAQ:PRPO – Get Rating)’s share price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.69 and traded as low as $0.44. Precipio shares last traded at $0.45, with a volume of 442,855 shares changing hands. Wall Street Analysts […]
June 11, 2023
Revvity (NYSE:RVTY – Get Rating) and Precipio (NASDAQ:PRPO – Get Rating) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability. Profitability This table compares Revvity and Precipio’s net margins, return on equity […]
June 9, 2023
Precipio (NASDAQ:PRPO – Get Rating) and Revvity (NYSE:RVTY – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations. Analyst Recommendations This is a summary of current ratings and recommmendations for […]
March 25, 2022
Precipio, Inc. (NASDAQ:PRPO – Get Rating) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.95 and traded as low as $1.35. Precipio shares last traded at $1.37, with a volume of 35,055 shares changing hands. The business’s 50-day moving average is $1.36 and its […]